About Us
Welcome to Keltic Pharma
At Keltic Pharma, we are pioneers in biotechnology, driven by a shared vision to revolutionise drug discovery. Established in 2019 by three leading professors from the University of Glasgow, our foundation is built upon a wealth of expertise and a commitment to advancing scientific knowledge. Professors Andrew Tobin, Graeme Milligan, and Andrew Jameson, each a world expert in their respective fields, came together to create an innovative biotech company with a mission to make a profound impact on healthcare.
Our Proprietary Platform: PEPSMOL©
At the heart of Keltic Pharma lies our ground-breaking proprietary platform – PEPSMOL©. This innovative technology is poised to redefine the landscape of drug discovery. PEPSMOL© empowers us to delve into uncharted territories, providing a versatile foundation that holds the promise of transformative breakthroughs.
Our In-House Drug Discovery Programmes
Driven by a commitment to addressing critical healthcare challenges, we have strategically focused our efforts on four
in-house drug discovery programs. Currently, our teams are dedicated to advancing research in the areas of Alzheimer's disease, schizophrenia, severe asthma and malaria. These programmes reflect our dedication to making a tangible difference in the lives of individuals affected by these conditions.
Meet Our Visionary Founders
Professor Andrew Tobin:
An Authority in Biology Receptors
Recipient of the British Pharmacological Society’s prestigious Vane Medal, Professor Andrew Tobin is a leading authority in a class of cell surface receptors called G protein coupled receptors (GPCRs). His ground-breaking work has not only shaped academic discussion and research but also serves as the cornerstone of Keltic Pharma's scientific pursuits.
Professor Graeme Milligan: A Visionary in Molecular Pharmacology
Professor Graeme Milligan, a leading expert in molecular pharmacology, brings a wealth of experience to our leadership team. Early involvement in the development of both Arena Pharmaceuticals, acquired by Pfizer for $6.7 billion in 2022, and the NASDAQ-listed Cara Therapeutics, attests to his impactful contributions to the field.
Professor Andrew Jameson: Empowering Discovery at the Molecular Frontier
An expert in chemical biology, Professor Andrew Jameson contributes his deep understanding of the intricate interplay between chemistry and biology to our leadership team. His commitment to pushing the boundaries of knowledge aligns seamlessly with Keltic Pharma's mission and he has been the architect of our proprietary platform PEPSMOL©.
Learn more about Keltic Pharma Therapeutics
We are happy to an answer questions about our company, malaria, drug discovery platform technology and partnering opportunities.